Tocqueville Asset Management L.P. Decreases Holdings in TScan Therapeutics, Inc. $TCRX

Key Points

• Tocqueville Asset Management L.P. sold 233,870 shares of TScan Therapeutics, reducing its holdings by 89.7% to 27,000 shares worth $37,000 by the end of the quarter.
• Several other institutional investors have made various adjustments to their stakes in TScan, with Bank of America increasing its holdings by 54.4% in the fourth quarter.
• TScan Therapeutics reported earnings of ($0.28) per share, meeting analyst expectations, with revenue of $3.08 million, significantly above the consensus estimate of $1.31 million.

Tocqueville Asset Management L.P. cut its position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) by 89.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,000 shares of the company's stock after selling 233,870 shares during the quarter. Tocqueville Asset Management L.P.'s holdings in TScan Therapeutics were worth $37,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. ProShare Advisors LLC bought a new position in TScan Therapeutics during the fourth quarter worth $40,000. Squarepoint Ops LLC bought a new position in TScan Therapeutics during the fourth quarter worth $59,000. Wells Fargo & Company MN boosted its stake in TScan Therapeutics by 41.1% during the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock worth $59,000 after acquiring an additional 5,694 shares in the last quarter. Heck Capital Advisors LLC bought a new position in TScan Therapeutics during the fourth quarter worth $61,000. Finally, Shay Capital LLC bought a new position in TScan Therapeutics during the fourth quarter worth $65,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.

TScan Therapeutics Stock Up 7.5%

Shares of TCRX stock traded up $0.13 on Friday, hitting $1.87. The stock had a trading volume of 353,254 shares, compared to its average volume of 248,782. The business has a 50 day moving average of $1.69 and a 200 day moving average of $1.63. The stock has a market cap of $106.12 million, a price-to-earnings ratio of -1.72 and a beta of 0.99. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.06 and a quick ratio of 7.06. TScan Therapeutics, Inc. has a 12-month low of $1.02 and a 12-month high of $6.2250.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.28) EPS for the quarter, meeting the consensus estimate of ($0.28). The company had revenue of $3.08 million during the quarter, compared to the consensus estimate of $1.31 million. TScan Therapeutics had a negative net margin of 1,964.88% and a negative return on equity of 63.33%. As a group, analysts expect that TScan Therapeutics, Inc. will post -1.12 EPS for the current year.

Analyst Upgrades and Downgrades

TCRX has been the topic of several research analyst reports. Wedbush reissued an "outperform" rating and set a $7.00 target price on shares of TScan Therapeutics in a research note on Tuesday, August 12th. Wall Street Zen raised shares of TScan Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, July 12th. Finally, HC Wainwright dropped their price objective on shares of TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, TScan Therapeutics presently has a consensus rating of "Buy" and an average target price of $7.80.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.